Insider

Medline Inc.

MDLN Health Care · 4 analyses · 5 expectations tracked

Medline reported $7.9B in revenue (+10.4% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 5 open management expectations for this company. 2 insider sales recorded. Its latest periodic filing added 25 new risk factors.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Medline погодила викуп акцій на $200 млн

Компанія Medline Inc. погодилася викупити акції та частки на суму $200 млн у межах приватної угоди, яка залежить від завершення вторинного розміщення акцій. Це рішення дозволить компанії скасувати частину викуплених паперів, а сама угода про викуп була схвалена аудиторським комітетом ради директорів.

· Medline Inc.
What changed

Medline reports revenue growth, lower operating income

Medline Inc. reported results for the third quarter of 2026: revenue rose to $7.86 billion. Meanwhile, the company’s operating income fell 12.9% compared to the same quarter last year and 26.3% for the first nine months of the year compared to the same period in 2025.

· Medline Inc.

Company history

October 2026

Medline Inc. experienced significant insider stock divestments, board leadership changes, and a voluntary product withdrawal during October 2026.

  • Between October 2, 2026 and October 6, 2026, insiders disposed of 20,678,630 shares in 5 transactions for a total value of 721,644,227.38 USD, leaving 77,225,493 shares owned. Source
  • On October 8, 2026, an insider disposed of 7,816,987 shares at a weighted average price of 35.15 USD, totaling 274,767,093.05 USD, leaving 69,408,506 shares owned. Source
  • On October 13, 2026, Joseph P. Baratta notified the Board of Medline Inc. of his decision to resign from the Board, effective December 31, 2026. Source
  • On October 14, 2026, Medline Inc. initiated a voluntary field action to remove and discontinue Medline Brand beds and accessories from its Front Line Care category, which generated approximately $60 million in net sales for the twelve months ended June 27, 2026. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 26, 2026, filed November 4, 2026. SEC

LatestEarlierChange
Revenue quarter$7.9B$7.1B+10.4%
Operating income quarter$500M$574M-12.9%
Net income quarter$318M——
Diluted EPS quarter$0.22——
Operating cash flow year to date$2.2B$1.5B+42.0%
Cash and cash equivalents balance$2.3B$1.9B+19.7%
Long-term debt balance$12.6B$12.5B+0.5%

Next results expected around February 3, 2027 (estimate: the quarter ending about December 26, 2026 plus the 39 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

6.6Q1 '268.6%6.9Q2 '269.3%7.1Q3 '268.1%7.8Q4 '25*5.5%7.4Q1 '265.7%7.7Q2 '265.1%7.9Q3 '266.4%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Medline Inc. MDLN$7.9B+10.4%6.4%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The secondary offering of Class A common stock is expected to close on November 23, 2026.

    Said November 18, 2026 · Period named: November 23, 2026 · Source · Our article

    Not yet checked against later reports.

  • Medline and Medline Holdings intend to repurchase equity interests in a total amount based on a $200,000,000 quotient, determined by the price of secondary shares in an underwritten offering.

    Said November 18, 2026 · Source · Our article

    Not yet checked against later reports.

  • Full year 2026 Adjusted EBITDA guidance excludes $324 million of net tariff refunds recorded through the first nine months of 2026.

    Said November 4, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

  • Reaffirming Adjusted EBITDA guidance of $3.3 billion to $3.4 billion.

    Said November 4, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

  • Raising full year 2026 Organic Sales guidance to 10.0% to 10.5%.

    Said November 4, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed November 4, 2026 compared with the 10-Q filed August 5, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (25)

  • | September 26, 2026 | | September 27, 2025 | | September 26, 2026 | | September 27, 2025
  • Issuance of shares under employee stock plans | 1 | | — | | — | | — | | — | | — | | — | | — | | —
  • Balance, September 26, 2026 | 879 | $ | — | | 437 | $ | — | | $ | 11,428 | | $ | 377 | | $ | (4) | | $ | 7,585 | | $ | 19,386

Dropped (14)

  • We file electronically with the U.S. Securities and Exchange Commission (the “SEC”) our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements and other forms or reports as required. Our filings with the SEC are available to the public at the SEC’s website at www.sec.gov. We also use our investor relations website at ir.medline.com, press releases, public conference calls and webcasts, and social media as routine channels of distribution to communicate important, and often material, information about Medline to investors and the public,…
  • Balance, March 28, 2026 | 846 | $ | — | | 468 | | $ | — | | $ | 11,132 | | $ | 122 | | $ | 18 | | $ | 8,077 | | $ | 19,349
  • Balance, March 29, 2025 | 128 | $ | 239 | | 104 | $ | 129 | | $ | 368 | | 16,723 | $ | 16,294 | | 764 | $ | 140 | | 23 | $ | 49 | | $ | 7 | | $ | 16,490

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 15, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
October 8, 2026GIC Private LtdSale7,816,987$35.15$274,767,093SEC
October 6, 2026GIC Private LtdSale20,678,630$34.90$721,644,227SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
Capital Research Global Investors47,756,528$1,657,164,017+19.5%Q3 2026
Fidelity (FMR)44,424,934$1,541,545,193-5.4%Q3 2026
BlackRock26,551,775$921,346,611+0.6%Q3 2026
State Street9,878,097$342,769,966+16.9%Q3 2026
Norges Bank (Norway's sovereign fund)8,475,413$334,270,289—Q2 2026
Geode Capital Management9,068,896$314,022,775+14.1%Q3 2026
Citadel Advisors2,082,861$72,275,277+6,291.9%Q3 2026
Soros Fund Management1,003,364$34,816,731-38.8%Q3 2026
Renaissance Technologies441,100$15,306,170+207.0%Q3 2026
Millennium Management207,758$7,209,203-80.5%Q3 2026
Two Sigma Investments92,170$3,198,299-52.6%Q3 2026
Wellington Management62,515$2,465,591—Q2 2026
Bridgewater Associates20,398$707,811+2.8%Q3 2026
T. Rowe Price3,541,067$122,876-28.1%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.